Andrew V. Kossenkov

18.4k citations

181 papers · 8.5k indexed · 3 hit papers · h-index 49

Co-authors: Rugang Zhang Louise C. Showe David W. Speicher Benjamin G. Bitler José R. Conejo-García Hsin‐Yao Tang Qin Liu Katherine M. Aird
Topics: RNA modifications and cancer (20 papers)Viral-associated cancers and disorders (19 papers)Immune cells in cancer (17 papers)
Cited by: Cancer Research Molecular Biology Oncology
Journals: Proceedings of the National Academy of Sciences Nucleic Acids Research Journal of Biological Chemistry
Partner nations: United States Italy Russia

In The Last Decade

Andrew V. Kossenkov

171 papers receiving 8.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers

2015 492 citations Benjamin G. Bitler, Andrew V. Kossenkov et al. profile →
NAD+ metabolism governs the proinflammatory senescence-associated secretome

2019 282 citations Timothy Nacarelli, Takeshi Fukumoto et al. Nature Cell Biology profile →
The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer

2022 205 citations Aaron R. Goldman, Hsin‐Yao Tang et al. profile →

Peers

Countries citing papers authored by Andrew V. Kossenkov

Since Specialization

Citations

This map shows the geographic impact of Andrew V. Kossenkov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew V. Kossenkov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew V. Kossenkov more than expected).

Fields of papers citing papers by Andrew V. Kossenkov

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew V. Kossenkov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew V. Kossenkov. The network helps show where Andrew V. Kossenkov may publish in the future.

Co-authorship network of co-authors of Andrew V. Kossenkov

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew V. Kossenkov. A scholar is included among the top collaborators of Andrew V. Kossenkov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew V. Kossenkov. Andrew V. Kossenkov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	TXNRD1 drives the innate immune response in senescent cells with implications for age-associated inflammation 2024 ·Nature Aging ·Hao Xue,Bo Zhao,(unknown),(unknown),(unknown),Xin Xu,(unknown),Hongzhuang Peng,Hsin‐Yao Tang,Aaron Havas,Andrew V. Kossenkov,Shelley L. Berger,Peter D. Adams,David W. Speicher,D. Schultz,Ronen Marmorstein,Kenneth S. Zaret,Rugang Zhang	17
2	Targeting Fatty Acid Reprogramming Suppresses CARM1-expressing Ovarian Cancer 2023 ·Cancer Research Communications ·(unknown),Aaron R. Goldman,Hsin‐Yao Tang,Andrew V. Kossenkov,(unknown),Wei Zhou,Meenhard Herlyn,Jianhuang Lin,Rugang Zhang	8
3	Intercellular hif1α reprograms mammary progenitors and myeloid immune evasion to drive high-risk breast lesions 2023 ·Journal of Clinical Investigation ·Irene Bertolini,Michela Perego,Yulia Nefedova,Cindy Lin,(unknown),Peter Vogel,Jagadish C. Ghosh,Andrew V. Kossenkov,Dario C. Altieri	8
4	Mitochondrial fitness and cancer risk 2022 ·PLoS ONE ·Andrew V. Kossenkov,(unknown),Faiyaz Notta,Gun-Ho Jang,Julie M. Wilson,Steven Gallinger,Daniel Cui Zhou,Li Ding,Jagadish C. Ghosh,Michela Perego,(unknown),Marco Locatelli,Marie E. Robert,Valentina Vaira,Dario C. Altieri	9
5	Small extracellular vesicle-mediated ITGB6 siRNA delivery downregulates the αVβ6 integrin and inhibits adhesion and migration of recipient prostate cancer cells 2022 ·Cancer Biology & Therapy ·Shiv Ram Krishn,(unknown),(unknown),(unknown),(unknown),(unknown),Andrew V. Kossenkov,Qin Liu,Eva Corey,Dario C. Altieri,Lucia R. Languino	18
6	NFκB activation by hypoxic small extracellular vesicles drives oncogenic reprogramming in a breast cancer microenvironment 2022 ·Oncogene ·Irene Bertolini,Michela Perego,Jagadish C. Ghosh,Andrew V. Kossenkov,Dario C. Altieri	11
7	Targeting ACSS2 with a Transition-State Mimetic Inhibits Triple-Negative Breast Cancer Growth 2021 ·Cancer Research ·Katelyn D. Miller,(unknown),Caroline Perry,(unknown),(unknown),(unknown),(unknown),(unknown),Y. V. V. Srikanth,Joel Cassel,Emmanuel Skordalakes,Andrew V. Kossenkov,Joseph M. Salvino,Zachary T. Schug	67
8	A multi-omics approach to Epstein-Barr virus immortalization of B-cells reveals EBNA1 chromatin pioneering activities targeting nucleotide metabolism 2021 ·PLoS Pathogens ·Jason Lamontagne,Samantha S. Soldan,Chenhe Su,Andreas Wiedmer,Kyoung‐Jae Won,Fang Lü,Aaron R. Goldman,Jayamanna Wickramasinghe,Hsin‐Yao Tang,David W. Speicher,Louise C. Showe,Andrew V. Kossenkov,Paul M. Lieberman	28
9	m6A-independent genome-wide METTL3 and METTL14 redistribution drives the senescence-associated secretory phenotype 2021 ·Nature Cell Biology ·Pingyu Liu,Fuming Li,Jianhuang Lin,Takeshi Fukumoto,Timothy Nacarelli,Hao Xue,Andrew V. Kossenkov,M. Celeste Simon,Rugang Zhang	118
10	Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations 2019 ·Molecular Cancer Therapeutics ·Pyoung Hwa Park,Tomomi M. Yamamoto,Hua Li,Allen L. Alcivar,Bing Xia,Yifan Wang,Andrea J. Bernhardy,Kristen M. Turner,Andrew V. Kossenkov,Zachary L. Watson,Kian Behbakht,Silvia Casadei,Elizabeth M. Swisher,Paul S. Mischel,Neil Johnson,Benjamin G. Bitler	20
11	Myc-mediated transcriptional regulation of the mitochondrial chaperone TRAP1 controls primary and metastatic tumor growth 2019 ·Journal of Biological Chemistry ·Ekta Agarwal,Brian J. Altman,Jae Ho Seo,Jagadish C. Ghosh,Andrew V. Kossenkov,Hsin‐Yao Tang,Shiv Ram Krishn,Lucia R. Languino,Dmitry I. Gabrilovich,David W. Speicher,Chi V. Dang,Dario C. Altieri	24
12	Inhibition of Casein Kinase 2 Disrupts Differentiation of Myeloid Cells in Cancer and Enhances the Efficacy of Immunotherapy in Mice 2018 ·Cancer Research ·Ayumi Hashimoto,Chan Gao,Jérôme Mastio,Andrew V. Kossenkov,Scott I. Abrams,Ashok V. Purandare,Heshani Desilva,Susan Wee,J.F. Hunt,Maria Jure–Kunkel,Dmitry I. Gabrilovich	43
13	Syntaphilin Ubiquitination Regulates Mitochondrial Dynamics and Tumor Cell Movements 2018 ·Cancer Research ·Jae Ho Seo,Ekta Agarwal,Kelly G. Bryant,M. Cecilia Caino,Eui Tae Kim,Andrew V. Kossenkov,Hsin‐Yao Tang,Lucia R. Languino,Dmitry I. Gabrilovich,Andrew R. Cohen,David W. Speicher,Dario C. Altieri	42
14	HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors 2016 ·Cancer Research ·Anna Budina-Kolomets,Marie R. Webster,Julia I-Ju Leu,Matthew Jennis,Clemens Krepler,(unknown),Andrew V. Kossenkov,Wei Xu,Giorgos C. Karakousis,Lynn M. Schuchter,Ravi K. Amaravadi,Hong Wu,Xiangfan Yin,Qin Liu,Yiling Lu,Gordon B. Mills,Xiaowei Xu,Donna L. George,Ashani T. Weeraratna,Maureen E. Murphy	34
15	BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer 2016 ·Cancer Research ·Yuhki Yokoyama,Hengrui Zhu,Jeong Heon Lee,Andrew V. Kossenkov,Sherry Y. Wu,Jayamanna Wickramasinghe,Xiangfan Yin,Katherine C. Palozola,Alessandro Gardini,Louise C. Showe,Kenneth S. Zaret,Qin Liu,David W. Speicher,José R. Conejo-García,James E. Bradner,Zhiguo Zhang,Anil K. Sood,Tamás Ördög,Benjamin G. Bitler,Rugang Zhang	116
16	ID1 Promotes Breast Cancer Metastasis by S100A9 Regulation 2014 ·Molecular Cancer Research ·Kiranmai Gumireddy,Anping Li,Andrew V. Kossenkov,Kathy Q. Cai,Qin Liu,Jinchun Yan,Hua Xu,Louise C. Showe,Lin Zhang,Qihong Huang	35
17	Lineage and species-specific long noncoding RNAs during erythro-megakaryocytic development 2014 ·Blood ·Vikram R. Paralkar,Tejaswini Mishra,Jing Luan,Yu Yao,Andrew V. Kossenkov,Stacie M. Anderson,Margaret C. Dunagin,Maxim Pimkin,(unknown),Diana Sun,Neeraja Konuthula,Arjun Raj,Xiuli An,Narla Mohandas,David M. Bodine,Ross C. Hardison,Mitchell J. Weiss	133
18	Chk2 Phosphorylation of Survivin-ΔEx3 Contributes to a DNA Damage–Sensing Checkpoint in Cancer 2012 ·Cancer Research ·Alessia Lopergolo,Michele Tavecchio,Sofia Lisanti,Jagadish C. Ghosh,Takehiko Dohi,Alice Faversani,Valentina Vaira,Silvano Bòsari,Nobuhiko Tanigawa,Domenico Delia,Andrew V. Kossenkov,Louise C. Showe,Dario C. Altieri	15
19	Resection of Non–Small Cell Lung Cancers Reverses Tumor-Induced Gene Expression Changes in the Peripheral Immune System 2011 ·Clinical Cancer Research ·Andrew V. Kossenkov,Anil Vachani,Celia Chang,Calen Nichols,(unknown),Wen-Hwai Horng,William N. Rom,Steven Μ. Albelda,Michael K. Showe,Louise C. Showe	42
20	Gene Expression Profiles in Peripheral Blood Mononuclear Cells Can Distinguish Patients with Non–Small Cell Lung Cancer from Patients with Nonmalignant Lung Disease 2009 ·Cancer Research ·Michael K. Showe,Anil Vachani,Andrew V. Kossenkov,Malik Yousef,Calen Nichols,Elena V. Nikonova,Celia Chang,John C. Kucharczuk,(unknown),Elliot Wakeam,(unknown),David J. Speicher,William N. Rom,Steven Μ. Albelda,Louise C. Showe	125

About Andrew V. Kossenkov

Andrew V. Kossenkov is a scholar working on Virology, Cancer Research and Immunology, having authored 181 papers that have together received 8.5k indexed citations. Recurring topics across this work include RNA modifications and cancer (20 papers), Viral-associated cancers and disorders (19 papers) and Immune cells in cancer (17 papers). The work is most often cited by research in Cancer Research (1.8k citations), Molecular Biology (5.5k citations) and Oncology (2.1k citations). Andrew V. Kossenkov has collaborated with scholars based in United States, Italy and Russia. Frequent co-authors include Rugang Zhang, Louise C. Showe, David W. Speicher, Benjamin G. Bitler, José R. Conejo-García, Hsin‐Yao Tang, Qin Liu, Katherine M. Aird, Dario C. Altieri and Lucia R. Languino. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact